Outpatients Service of Psychiatry Department. Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, 08025, Spain
NCT Number: NCT00931775
The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Barcelona, Catalonia, 08025, Spain
Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram + placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected from a general hospital.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pill orally administered. 15 mg/day t.i.d.
Time frame: 8 time points through 6 weeks
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Other
Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder
Acronym: CIT-PIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial DetailsNCT05224063
Depressive Disorder, Depressive Disorder, Major
Stanford, California, United States
View Trial Details